{
    "2021-08-07": [
        [
            {
                "time": "2021-08-07",
                "orginal_text": "锂电领跑比亚迪市值暴增 生物疫苗恐复星医药重挫",
                "features": {
                    "keywords": [
                        "锂电",
                        "比亚迪",
                        "市值暴增",
                        "生物疫苗",
                        "复星医药",
                        "重挫"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "新能源",
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-08-07",
                "orginal_text": "千亿大白马股东刚减持完又宣布增持，能稳住吗？",
                "features": {
                    "keywords": [
                        "千亿大白马",
                        "减持",
                        "增持"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-07",
                "orginal_text": "上市公司正面负面新闻2021年8月7日星期六",
                "features": {
                    "keywords": [
                        "上市公司",
                        "正面负面新闻"
                    ],
                    "sentiment_score": 0.0,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-08-07",
                "orginal_text": "长春高新：公司贯彻以医药为主、房地产为辅的产业发展定位，推进地产板块平稳发展，同时无加码房地产业务安排",
                "features": {
                    "keywords": [
                        "长春高新",
                        "医药",
                        "房地产",
                        "产业定位",
                        "平稳发展"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "房地产"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-08-07",
                "orginal_text": "长春高新：公司预计短期内生长激素产品不会进入国家集采，目前只有个别省份拟进行集采事项，相对来说影响较小",
                "features": {
                    "keywords": [
                        "长春高新",
                        "生长激素",
                        "国家集采",
                        "影响较小"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-07",
                "orginal_text": "长春高新：在生长激素领域，金赛药业拥有“纯化的PEG化人生长激素缀合物及其药物制剂”的发明专利和“含PEG化人生长激素缀合物的药物及其应用”等发明专利，上述两项专利申请日期为2008年，保护期20年",
                "features": {
                    "keywords": [
                        "长春高新",
                        "生长激素",
                        "金赛药业",
                        "发明专利",
                        "专利保护期"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}